Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification.

Male Humans Prostate / pathology Prostatic Neoplasms / pathology Neoplasm Grading Prostate-Specific Antigen Adenocarcinoma / pathology

Journal

European urology
ISSN: 1873-7560
Titre abrégé: Eur Urol
Pays: Switzerland
ID NLM: 7512719

Informations de publication

Date de publication:
04 2023
Historique:
received: 28 06 2022
revised: 23 08 2022
accepted: 01 09 2022
pubmed: 7 10 2022
medline: 15 3 2023
entrez: 6 10 2022
Statut: ppublish

Résumé

We present the rationale for keeping the "cancer" label for grade group 1 (GG1) prostate cancer. Maintaining GG1 as the lowest grade outweighs the potential benefits that a benign designation may bring. Patient and surgeon education on the vital role of active surveillance for GG1 cancers and avoidance of overtreatment should be the focus rather than such a drastic change in nomenclature.

Identifiants

DOI: 10.1016/j.eururo.2022.09.015 PMID: 36202687
pubmed: 36202687
pii: S0302-2838(22)02644-6
doi: 10.1016/j.eururo.2022.09.015
pii:
doi:

Substances chimiques

Prostate-Specific Antigen EC 3.4.21.77

Types de publication

Editorial

Langues

eng

Sous-ensembles de citation

IM

Pagination

301-303

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2022 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Auteurs

George J Netto (GJ)

Department of Pathology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: gnetto@uabmc.edu.

Mahul B Amin (MB)

Department of Pathology and Laboratory Medicine, University of Tennessee Health Science Center, Memphis, TN, USA; Department of Urology, USC Keck School of Medicine, Los Angeles, CA, USA.

Eva M Compérat (EM)

Department of Pathology, Medical University of Vienna, General Hospital of Vienna, Vienna, Austria.

Anthony J Gill (AJ)

Sydney Medical School, University of Sydney, Sydney, Australia; NSW Health Pathology, Department of Anatomical Pathology, Royal North Shore Hospital, Sydney, Australia; Pathology Group, Kolling Institute of Medical Research, Royal North Shore Hospital, Sydney, Australia.

Arndt Hartmann (A)

Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.

Holger Moch (H)

Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.

Santosh Menon (S)

Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.

Maria R Raspollini (MR)

Histopathology and Molecular Diagnostics, University Hospital Careggi, Florence, Italy.

Mark A Rubin (MA)

Department for BioMedical Research, Bern Center for Precision Medicine, University of Bern and Inselspital, Bern, Switzerland.

John R Srigley (JR)

Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.

Puay Hoon Tan (P)

Division of Pathology, Singapore General Hospital, Singapore.

Satish K Tickoo (SK)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Toyonori Tsuzuki (T)

Department of Surgical Pathology, Aichi Medical University Hospital, Nagakut, Japan.

Samra Turajlic (S)

Francis Crick Institute and Royal Marsden NHS Foundation Trust, London, UK.

Ian Cree (I)

International Agency for Research on Cancer, World Health Organization, Lyon, France.

Daniel M Berney (DM)

Barts Cancer Institute, Queen Mary University of London and Department of Cellular Pathology, Barts Health NHS Trust, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Prostate Adenocarcinoma Grade Group 1:...
questionsmedicales.fr › Tissus › Glandes exocrines › Prostate › Prostate Adenocarcinoma Grade Group 1:...
questionsmedicales.fr › Maladies urogénitales › Tumeurs de l'appareil urogénital › Tumeurs de l'appareil génital mâle › Tumeurs de la prostate › Prostate Adenocarcinoma Grade Group 1:...
questionsmedicales.fr › Diagnostic › Pronostic › Grading des tumeurs › Prostate Adenocarcinoma Grade Group 1:...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › Antigène spécifique de la prostate › Prostate Adenocarcinoma Grade Group 1:...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs épithéliales épidermoïdes et glandulaires › Carcinomes › Adénocarcinome › Prostate Adenocarcinoma Grade Group 1:...